Eradicating Helicobacter pylori in peptic ulcer disease reduces medical costs in the community

Helicobacter

Volumn 13, Issue 5, 2008, Pages 346-351

  Sone, Yasuhiro ^a,b   Kumada, Takashi ^a,b   Toyoda, Hidenori ^a   Yokoyama, Mitsuyoshi ^b   Kato, Mototsugu ^c   Asaka, Masahiro ^c  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

^b Seino Kenpo Clinic   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cost effective analysis; Eradication; Helicobacter pylori; Peptic ulcer disease

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; FAMOTIDINE; LANSOPRAZOLE;

ADULT; ARTICLE; COMMUNITY CARE; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DECISION MAKING; ERADICATION THERAPY; FEMALE; HEALTH CARE COST; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; RECURRENT DISEASE; UREA BREATH TEST;

COHORT STUDIES; FEMALE; HEALTH CARE COSTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; TIME FACTORS;

HELICOBACTER PYLORI;

EID: 49749122695     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2008.00623.x     Document Type: Article

References (33)

1. Van del Hulst RWM, Rauws EAJ, Köycü B et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology 1997 113: 1082 6.
2. Asaka M, Kato M, Sugiyama T et al. Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J Gastroenterol 2003 38: 339 47.
3. NIH consensus development panel on Helicobacter pylori in peptic ulcer disease. Helicobacter pylori in peptic ulcer disease. JAMA 1994 272: 65 9.
4. Soll AH. Medical treatment of peptic ulcer disease. JAMA 1996 275: 622 9.
5. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56: 772 81.
6. Lam SK, Talley NJ. Report of the 1997 Asia Pacific consensus conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998 13: 1 12.
7. Asaka M, Satoh K, Sugano K et al. Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 2001 6: 177 86.
8. Sonnenberg A, Townsend WF. Costs of duodenal ulcer therapy with antibiotics. Arch Intern Med 1995 155: 922 8.
9. Imperiale TF, Speroff T, Cebul RD, McCullough AJ. A cost analysis of alternative treatments for duodenal ulcer. Ann Intern Med 1995 123: 665 72.
10. O'Brien B, Goeree R, Mohamed AH, Hunt R. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch Intern Med 1995 155: 1958 64.
11. Jönsson B. Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease. Scand J Gastroenterol 1996 31: 90 5.
12. Vakil N, Fennerty MB. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer. Am J Gastroenterol 1996 91: 239 45.
13. Fendrick AM, McCort JT, Chernew ME et al. Immediate eradication of Helicobacter pylori in patients with previously documented peptic ulcer disease: clinical and economic effects. Am J Gastroenterol 1997 92: 2017 24.
14. Badia X, Segú JL, Ollé A, Brosa M, Monés J, Ponte LG. Cost-effectiveness analysis of different strategies for treating duodenal ulcer. Helicobacter pylori eradication versus anti-secretory treatment. Pharmacoeconomics 1997 11: 367 76.
15. Duggan AE, Tolley K, Hawkey CJ, Logan RFA. Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model. BMJ 1998 316: 1648 54.
16. Habu Y, Inokuchi H, Kiyota K et al. Economic evaluation of Helicobacter pylori eradication for the treatment of duodenal ulcer disease in Japan: a decision analysis to assess eradication strategy in comparison with a conventional strategy. J Gastroenterol Hepatol 1998 13: 280 7.
17. Ikeda S, Tamamuro T, Hamashima C, Asaka M. Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan. Aliment Pharmacol Ther 2001 15: 1777 85.
18. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004 99: 1833 55.
19. Sonnenberg A, Schwartz JS, Cutler AF, Vakil N, Bloom BS. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Arch Intern Med 1998 158: 852 60.
20. Levin TR, Schmittdiel JA, Henning JM et al. A cost analysis of a Helicobacter pylori eradication strategy in a large health maintenance organization. Am J Gastroenterol 1998 93: 743 7.
21. 2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy. A randomized controlled trial in patients with continuing pain after duodenal ulcer. Pharmacoeconomics 1999 16: 355 65.
22. Yamasaki T. Cost-effectiveness of Helicobacter pylori eradication therapy at a company occupational health clinic in Japan. JUOEH 2002 24: 161 76.
23. Nishikawa K, Sugiyama T, Kato M et al. A prospective evaluation of new rapid urease tests before and after eradication treatment of Helicobacter pylori, in comparison with histology, culture and 13C-urea breath test. Gastrointest Endosc 2000 51: 164 8.
24. Ohara S, Kato M, Asaka M, Toyoda T. Studies of 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan. J Gastroenterol 1998 33: 6 13.
25. Asaka M, Kimura T, Kudo M et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 1992 102: 760 6.
26. Fukuda Y, Tomita T, Hori K, Tamura K, Shimoyama T. Epidemiology of H. pylori infection. Nippon Rinsho 2001 59: 234 8.
27. Tsuji H, Kohli Y, Fukumitsu S et al. Helicobacter pylori-negative gastric and duodenal ulcers. J Gastroenterol 1999 34: 455 60.
28. Nishikawa K, Sugiyama T, Kato M et al. Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur J Gastroenterol Hepatol 2000 12: 635 40.
29. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001 345: 784 9.
30. Yamamori K, Fujiwara Y, Shiba M et al. Prevalence of symptomatic gastro-oesophageal reflux disease in Japanese patients with peptic ulcer disease after eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2004 20: 107 11.
31. di Mario F, Stefani N, Bo ND et al. Natural course of functional dyspepsia after Helicobacter pylori eradication: a seven-year survey. Dig Dis Sci 2005 50: 2286 95.
32. Furuta T, Shirai N, Xiao F, Takashima M, Hanai H. Effect of Helicobacter pylori infection and its eradication on nutrition. Aliment Pharmacol Ther 2002 16: 799 806.
33. Kamada T, Hata J, Kusunoki H et al. Eradication of Helicobacter pylori increases the incidence of hyperlipidaemia and obesity in peptic ulcer patients. Dig Liver Dis 2005 37: 39 43.